 "AstraZeneca Q2 loss widens to Rs 27.96 crore")
The company has posted a net loss of Rs 1.22 crore in the July-September quarter period of the last fiscal.
AstraZeneca's total income from operation during the quarter under review was at Rs 114.67 against Rs 115.66 crore in the second quarter of the last fiscal, the company said in a filing to the BSE stock exchange.
More From This Section
The company said that the result was not comparable as AstraZeneca group companies had acquired the global diabetic business of Bristol Myers Squibb Company.
Consequent to the acquisition, it had entered into a consignment sale agreement with Bristol Myers Squibb India for a transition period from February 1, 2014, to May 31, 2014, post which the company is directly selling these products.
Shares of AstraZeneca today closed at Rs 912.15 on the BSE, up 4.85 per cent from previous closing.